Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers.
Mov Disord
; 33(6): 966-973, 2018 Jul.
Article
em En
| MEDLINE
| ID: mdl-29603409
ABSTRACT
BACKGROUND:
In 2015, the International Parkinson and Movement Disorder Society Task Force recommended research criteria for the estimation of prodromal PD.OBJECTIVES:
We aimed to evaluate, for the first time, the criteria in first-degree relatives of Ashkenazi Jewish G2019S-LRRK2 PD patients, who are considered a population at risk for developing PD, and assess the sensitivity and specificity of the criteria in identifying phenoconverters.METHODS:
Participants were evaluated longitudinally over a period of 5 years (average follow-up 49.2 ± 12.3 months). Likelihood ratios and probability estimations were calculated based on the International Parkinson and Movement Disorder Society Research Criteria for Prodromal Parkinson's Disease markers and examined for each assessment point.RESULTS:
One hundred twenty healthy carriers (49.53 ± 13.4 years; 54% female) and 111 healthy noncarriers (48.43 ± 15.79 years; 49% female) participated in this study. Probability scores were significantly higher in healthy carriers than healthy noncarriers (P < 0.0001). Of the 20 participants (8.6%) who met criteria for probable prodromal PD at baseline, 17 were healthy carriers. Participants who reached the threshold were older (P < 0.0001), had higher UPDRS-III (P < 0.001), lower cognitive function (P = 0.001), and more nonmotor symptoms (P < 0.0001), compared to those who did not. Ten participants were diagnosed with incident PD within 5 years from baseline resulting in a specificity of 91.82% (95% confidence interval 86.69-96.94), sensitivity of 80% (95% confidence interval 55.21-100), positive predictive value of 47.06% (95% confidence interval 23.33-70.79), and negative predictive value of 98.06% (95% confidence interval 95.39-100). All 10 phenoconvertors were G2019S-LRRK2 carriers.CONCLUSIONS:
The results showed the utility of using the criteria and high sensitivity and specificity in identifying prodromal PD in this high-risk unique cohort. These results may be valuable for future disease modification clinical trials. © 2018 International Parkinson and Movement Disorder Society.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Sociedades Médicas
/
Sintomas Prodrômicos
/
Serina-Treonina Proteína Quinase-2 com Repetições Ricas em Leucina
/
Transtornos dos Movimentos
/
Mutação
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Mov Disord
Assunto da revista:
NEUROLOGIA
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Israel